Compare DE & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DE | NVO |
|---|---|---|
| Founded | 1837 | 1923 |
| Country | United States | Denmark |
| Employees | 73100 | 69500 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.1B | 172.5B |
| IPO Year | 1994 | N/A |
| Metric | DE | NVO |
|---|---|---|
| Price | $566.02 | $35.97 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 11 |
| Target Price | ★ $618.11 | $51.00 |
| AVG Volume (30 Days) | 1.1M | ★ 15.4M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | 1.11% | ★ 3.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $45,684,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.88 | $3.30 |
| P/E Ratio | $240.07 | ★ $13.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $404.42 | $35.85 |
| 52 Week High | $674.19 | $81.44 |
| Indicator | DE | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 30.09 |
| Support Level | $457.94 | $35.85 |
| Resistance Level | $674.19 | $39.58 |
| Average True Range (ATR) | 14.06 | 0.85 |
| MACD | -2.81 | 0.33 |
| Stochastic Oscillator | 27.14 | 0.15 |
Deere is the world's leading manufacturer of agricultural equipment and a major producer of construction machinery. The company is divided into four reporting segments: production & precision agriculture, or PPA, small agriculture & turf, or SAT, construction & forestry, or CF, and financial services, or FS, its captive finance subsidiary. The core PPA business is the largest contributor to sales and profits by far. Geographically, Deere sales are 60% US/Canada, 17% Europe, 14% Latin America, and 9% rest of the world. Deere goes to market through a robust dealer network that includes over 2,000 dealer locations in North America with reach into over 100 countries. John Deere Financial provides retail financing for machinery to its customers and wholesale financing for dealers.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.